Nambara Sho, Sakaguchi Yoshihisa, Tsuda Yasuo, Kudou Kensuke, Kusumoto Eiji, Yoshida Rintaro, Kusumoto Tetsuya, Ikejiri Koji
Department of Gastroenterological Surgery and Clinical Research Institute Cancer Research Division, National Kyushu Medical Center, 1-8-1 Jigyohama Chuo-Ku, Fukuoka, 810-8563 Japan.
Int Cancer Conf J. 2022 Dec 21;12(2):100-103. doi: 10.1007/s13691-022-00582-7. eCollection 2023 Apr.
Primary malignant melanoma of the esophagus is a rare disease with a severely poor prognosis. Here, we report a patient with primary malignant melanoma of the esophagus surviving without recurrence after surgery and adjuvant therapy with nivolumab. The patient was a 60-year-old female with dysphagia. Esophagogastroscopy showed an elevated dark brown tumor in the lower thoracic esophagus. A histological examination of the biopsy revealed human melanoma black 45 and melan-A positivity. The patient was diagnosed with primary malignant melanoma of the esophagus and was treated with radical esophagectomy. As postoperative treatment, the patient was given nivolumab (240 mg/body) every 2 weeks. Although bilateral pneumothorax occurred after 2 courses, she recovered after chest drainage. Nivolumab treatment is still ongoing over 1 year after the surgery, and the patient has survived without recurrence. We conclude that nivolumab is an optimal option as a postoperative adjuvant treatment for PMME.
原发性食管恶性黑色素瘤是一种罕见疾病，预后极差。在此，我们报告一例原发性食管恶性黑色素瘤患者，在接受手术及纳武单抗辅助治疗后未复发存活。该患者为一名60岁女性，有吞咽困难症状。食管胃镜检查显示胸段食管下段有一隆起的深褐色肿瘤。活检组织学检查显示人黑色素瘤黑色45及黑色素A呈阳性。该患者被诊断为原发性食管恶性黑色素瘤，并接受了根治性食管切除术。作为术后治疗，患者每2周接受一次纳武单抗（240mg/体）治疗。尽管在2个疗程后出现双侧气胸，但经胸腔引流后恢复。手术后1年多纳武单抗治疗仍在进行，患者存活且未复发。我们得出结论，纳武单抗是原发性食管恶性黑色素瘤术后辅助治疗的最佳选择。
